Mercer International Stock Surges 45% on C$20 Million Canada Funding 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Amazon Secures 200 MW Wind Power Deals in Sweden 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Add as a preferred source on Google
CAMBRIDGE, Mass., April 11, 2018 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will webcast presentations from its Investor Day on Friday, May 4, 2018 starting at approximately 8:30 a.m. ET in New York.
Presentations will be given by members of Agios' leadership team and external speakers including:
- David Schenkein, M.D., Chief Executive Officer
- Scott Biller, Ph.D., Chief Scientific Officer
- Chris Bowden, M.D., Chief Medical Officer
- Andrew Hirsch, Chief Financial Officer and Head of Corporate Development
- Steve Hoerter, Chief Commercial Officer
- Darrin Miles, Vice President, IDH Program Management
- Susan Pandya, M.D., Senior Medical Director, Clinical Development
- Kevin Marks, Ph.D., Senior Director, Head of Cancer Biology
- Maeve Lowery, M.B., B.Ch., B.A.O, Trinity College Dublin
A live webcast of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The presentations are scheduled to begin at approximately 8:30 a.m. ET and conclude at 12:00 p.m. ET. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Investors:
Renee Leck, 617-649-8299
Senior Manager, Investor Relations
[email protected]
Media:
Holly Manning, 617-844-6630
Associate Director, Corporate Communications
[email protected]
